Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms

Thrombosis is a major cause of morbimortality in patients with chronic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). In the last decade, multiple lines of evidence support the role of leukocytes in thrombosis of MPN patients. Besides the increase in the number of cells, neutrophils and monocytes of MPN patients show a pro-coagulant activated phenotype. Once activated, neutrophils release structures composed of DNA, histones, and granular proteins, called extracellular neutrophil traps (NETs), which in addition to killing pathogens, provide an ideal matrix for platelet activation and coagulation mechanisms. Herein, we review the published literature related to the involvement of NETs in the pathogenesis of thrombosis in the setting of MPN; the effect that cytoreductive therapies and JAK inhibitors can have on markers of NETosis, and, finally, the novel therapeutic strategies targeting NETs to reduce the thrombotic complications in these patients.

Automated summary

In patients with chronic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), leukocytes play a significant role in thrombosis. Neutrophils and monocytes in MPN patients show a pro-coagulant activated phenotype and release extracellular neutrophil traps (NETs) that contribute to platelet activation and coagulation mechanisms. Therapeutic strategies targeting NETs may reduce thrombotic complications in these patients.